Survodutide
Two signals. Different populations. A record still being written.
Follow Subject One through laboratory assays, mouse research, diabetes and liver trials, phase 3 obesity results and questions still open.
Journey published October 27, 2026 · Evidence reviewed 2026-10-27
- 01Two signals, one moleculeLaboratory stage · Published November 2022
- 02The mouse keeps its own notebookAnimal stage · 2022 discovery paper
- 03The first human ledgerPhase 2 diabetes · Published December 14, 2023
- 04Beyond the bathroom scalePhase 2 MASH · Published June 7, 2024
- 05The larger roomSYNCHRONIZE-1 · Online June 7, 2026
- 06A result is not the last pageOctober 2026 · Diabetes results and an unstarted study
Today’s checkpoint
October 27, 2026: published phase 3 obesity and diabetes findings, earlier MASH biopsy evidence, and a newly updated trial plan without results. Benefit, tolerability and unanswered safety questions stay together.
Open the medicine’s evidence profile · Other journeys
Documented milestones, not every unpublished experiment. The story is fictional; each chapter identifies the real study population and source.